Aileron Therapeutics Stock Beneish M Score
| ALRN Stock | USD 2.86 0.12 4.38% |
Aileron | Beneish M Score |
At this time, it appears that Aileron Therapeutics is an unlikely manipulator. The earnings manipulation may begin if Aileron Therapeutics' top management creates an artificial sense of financial success, forcing the stock price to be traded at a high price-earnings multiple than it should be. In general, excessive earnings management by Aileron Therapeutics executives may lead to removing some of the operating profits from subsequent periods to inflate earnings in the following periods. This way, the manipulation of Aileron Therapeutics' earnings can lead to misrepresentations of actual financial condition, taking the otherwise loyal stakeholders on to the path of questionable ethical practices and plain fraud.
-4.08
Beneish M Score - Unlikely Manipulator
Aileron Therapeutics Beneish M-Score Indicator Trends
The cure to earnings manipulation is the transparency of financial reporting. It will typically remove the temptation of the top executives to inflate earnings (i.e., to promote the idea of 'winning at any cost'). Because a healthy internal audit department can enhance transparency, the board should promote the auditors' access to all the record-keeping systems across the enterprise. For example, if Aileron Therapeutics' auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back.
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | 111.3 M | 106 M |
|
| |||||
| Total Current Assets | 26.4 M | 18.3 M |
|
| |||||
| Non Current Assets Total | 92.1 M | 87.7 M |
|
| |||||
| Property Plant Equipment | 120.2 K | 126.5 K |
|
| |||||
| Depreciation And Amortization | 145 K | 119 K |
|
| |||||
| Selling General Administrative | 10.4 M | 11.4 M |
|
| |||||
| Total Current Liabilities | 4.5 M | 4.4 M |
|
| |||||
| Short Term Debt | 153.9 K | 96 K |
|
| |||||
| Gross Profit Margin | 0.36 | 0.41 |
|
|
Aileron Therapeutics Beneish M-Score Driver Matrix
One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to detect the potential manipulation of earnings. Understanding the correlation between Aileron Therapeutics' different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Aileron Therapeutics in a much-optimized way. Analyzing correlations between earnings drivers directly associated with dollar figures is the most effective way to find Aileron Therapeutics' degree of accounting gimmicks and manipulations.
Click cells to compare fundamentals
About Aileron Therapeutics Beneish M Score
M-Score is one of many grading techniques for value stocks. It was developed by Professor M. Daniel Beneish of the Kelley School of Business at Indiana University and published in 1999 under the paper titled The Detection of Earnings Manipulation. The Beneish score is a multi-factor model that utilizes financial identifiers to compile eight variables used to classify whether a company has manipulated its reported earnings. The variables are built from the officially filed financial statements to create a final score call 'M Score.' The score helps to identify companies that are likely to manipulate their profits if they show deteriorating gross margins, operating expenses, and leverage against growing revenue.
Depreciation And Amortization |
|
Aileron Therapeutics Earnings Manipulation Drivers
Although earnings manipulation is typically not the result of intentional misconduct by the c-level executives, it is still a widespread practice by the senior management of public companies such as Aileron Therapeutics. It is usually done by a series of misrepresentations of various accounting rules and operating activities across multiple financial cycles. The best way to spot the manipulation is to examine the historical financial statement to find inconsistencies in earning reports to find trends in assets or liabilities that are not sustainable in the future.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 26.5M | 16.3M | 48.5M | 22.0M | 106.0M | 111.3M | |
| Total Current Assets | 19.6M | 16.3M | 48.2M | 21.9M | 18.3M | 26.4M | |
| Non Current Assets Total | 6.9M | 15K | 304K | 134K | 87.7M | 92.1M | |
| Property Plant Equipment | 6.4M | 15K | 280K | 110K | 126.5K | 120.2K | |
| Depreciation And Amortization | 155K | 163K | 121K | 169K | 119K | 145.0K | |
| Selling General Administrative | 12.3M | 9.3M | 9.6M | 9.7M | 11.4M | 10.4M | |
| Total Current Liabilities | 5.8M | 4.0M | 4.5M | 3.4M | 4.4M | 4.5M | |
| Non Current Liabilities Total | 4.6M | 219K | 69K | 1.8M | 3.3M | 3.2M | |
| Net Debt | (279K) | (6.7M) | (3.4M) | (5.2M) | (17.3M) | (18.1M) | |
| Operating Income | (30.0M) | (20.5M) | (26.6M) | (27.6M) | (16.3M) | (17.1M) | |
| Total Cash From Operating Activities | (26.5M) | (20.5M) | (23.8M) | (24.9M) | (19.8M) | (20.8M) | |
| Investments | (2.7M) | 6.4M | (35.9M) | 26.5M | 21.1M | 22.1M | |
| Short Term Investments | 38.9M | 10.1M | 13.0M | 6.8M | 42.3M | 16.0M |
Aileron Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Aileron Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Aileron Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
About Aileron Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Aileron Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aileron Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aileron Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Aileron Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Aileron Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aileron Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Aileron Stock
Moving against Aileron Stock
The ability to find closely correlated positions to Aileron Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Aileron Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Aileron Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Aileron Therapeutics to buy it.
The correlation of Aileron Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Aileron Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Aileron Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Aileron Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Aileron Therapeutics Piotroski F Score and Aileron Therapeutics Altman Z Score analysis. To learn how to invest in Aileron Stock, please use our How to Invest in Aileron Therapeutics guide.You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aileron Therapeutics. If investors know Aileron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aileron Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.88) | Return On Assets (0.26) | Return On Equity (0.44) |
The market value of Aileron Therapeutics is measured differently than its book value, which is the value of Aileron that is recorded on the company's balance sheet. Investors also form their own opinion of Aileron Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Aileron Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aileron Therapeutics' market value can be influenced by many factors that don't directly affect Aileron Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aileron Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aileron Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aileron Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.